



# Market Announcement

31 May 2024

---

## BCAL Diagnostics Limited (ASX: BDX) – Suspension from Quotation

### Description

The securities of BCAL Diagnostics Limited ('BDX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of BDX, pending the release of an announcement regarding its capital raising.

### Issued by

ASX Compliance

For personal use only

**ASX Announcement**

31 May 2024

The Manager  
Issuers Department  
Australian Securities Exchange

**Request for Voluntary Suspension**

BCAL Diagnostics Limited (ASX:BDX) requests a voluntary suspension to the trading of the Company's securities until release of an announcement concerning the capital raise in progress.

In accordance with listing rule 17.2 the company advises that:

1. The voluntary suspension is necessary as the Board will require additional time to finalise the bookbuild in relation to the capital raising.
2. The Company wishes the voluntary suspension to last until as such time it makes an announcement to the market concerning the capital raise or Monday 3 June 2024, whichever is the earlier.
3. The Company is not aware of any reason why the voluntary suspension should not be granted, nor is it aware of any other information available at this stage that is necessary to inform the market about the voluntary suspension.

This request has been approved by the Board.

Yours faithfully



Guy Robertson  
Company Secretary